Strs Ohio Buys Shares of 63,590 Natera, Inc. $NTRA

Key Points

• Strs Ohio has invested approximately $8.99 million in Natera, Inc. by acquiring 63,590 shares during the first quarter of the year.
• Several major institutional investors, including Price T Rowe Associates and UBS AM, have significantly increased their stakes in Natera, indicating strong interest in the company.
• Despite reporting earnings that missed consensus estimates, Natera showed a 32.2% year-over-year revenue increase for the quarter, with a reported revenue of $546.60 million.

Strs Ohio bought a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 63,590 shares of the medical research company's stock, valued at approximately $8,992,000.

Several other institutional investors have also recently added to or reduced their stakes in NTRA. Price T Rowe Associates Inc. MD raised its stake in Natera by 56.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock valued at $1,490,144,000 after purchasing an additional 3,795,315 shares during the last quarter. Nuveen LLC acquired a new position in shares of Natera during the 1st quarter valued at about $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Natera by 140.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company's stock valued at $177,298,000 after acquiring an additional 732,156 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Natera by 9.9% during the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock valued at $1,041,055,000 after acquiring an additional 660,538 shares during the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of Natera by 8,233.5% during the 1st quarter. SG Americas Securities LLC now owns 397,924 shares of the medical research company's stock valued at $56,270,000 after acquiring an additional 393,149 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Insider Transactions at Natera

In other Natera news, Director Rowan E. Chapman sold 2,750 shares of the company's stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total value of $459,222.50. Following the completion of the transaction, the director owned 6,015 shares in the company, valued at $1,004,444.85. This represents a 31.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $166.77, for a total value of $500,310.00. Following the completion of the transaction, the insider directly owned 130,205 shares in the company, valued at approximately $21,714,287.85. The trade was a 2.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 56,423 shares of company stock worth $8,459,656 over the last 90 days. 5.63% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 price objective for the company in a research note on Monday, July 28th. Morgan Stanley reaffirmed an "overweight" rating and set a $195.00 price objective on shares of Natera in a research note on Sunday, August 10th. Stephens reaffirmed an "overweight" rating and set a $183.00 price objective on shares of Natera in a research note on Friday, August 15th. Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. Finally, Cowen reaffirmed a "buy" rating on shares of Natera in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $194.00.

Natera Price Performance

NASDAQ NTRA traded up $4.43 on Thursday, reaching $179.86. The company had a trading volume of 856,273 shares, compared to its average volume of 865,618. The firm has a market capitalization of $24.69 billion, a PE ratio of -94.17 and a beta of 1.68. Natera, Inc. has a 1 year low of $117.27 and a 1 year high of $183.00. The firm has a 50-day moving average of $156.38 and a 200-day moving average of $154.77.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm's revenue was up 32.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.